Experimental drug completely effective against Nipah virus infection in monkeys
(NIH/National Institute of Allergy and Infectious Diseases) The experimental antiviral drug remdesivir completely protected four African green monkeys from a lethal dose of Nipah virus, according to a new study in Science Translational Medicine from National Institutes of Health scientists and colleagues.
Publication date: Available online 26 March 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Marcus S. Shaker, John Oppenheimer, Mitchell Grayson, David Stukus, Nicholas Hartog, Elena W.Y. Hsieh, Nicholas Rider, Cullen M. Dutmer, Timothy K. Vander Leek, Harold Kim, Edmond S. Chan, Doug Mack, Anne K. Ellis, David Lang, Jay Lieberman, David Fleischer, David B.K. Golden, Dana Wallace, Jay Portnoy, Giselle Mosnaim
BackgroundTemporary disruption of sensory input can be studied relatively easily for vision or hearing by covering the eyes or ears. In contrast, closing the nostrils affects not only the sense of smell, but also the ability to breathe through the nose and humidify and warm inhaled air. We hypothesized that filling the olfactory cleft (OC) with dissolvable nasal dressing (foam) would temporarily block olfaction while respecting nasal airflow.MethodsIn 30 healthy volunteers, the OC was unilaterally obstructed in a back ‐to‐front fashion. Orthonasal and retronasal olfactory function were tested before and after foam appl...
ConclusionsSkin exposure to peanut did not lead to sensitization in this study, and monkeys did not experience anaphylaxis upon peanut challenge. However, monkeys produced increased peanut ‐specific IgG throughout peanut exposure, indicating that repeated skin exposure to peanut is immunogenic.
The oral immunomodulator is indicated for treatment of adults with relapsing remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features.Medscape Medical News
This article is protected by copyright. All rights reserved.
One chart explains why slowing the spread of the infection is nearly as important as stopping it.
Having trouble viewing this email? View it as a Web page. NIDCR's Spring 2020 E-Newsletter In this issue: NIDCR News Funding Opportunities NIH/HHS News Funding Notices Science Advances Subscribe to NICDR News Grantee News NIDCR News CDC’s COVID-19 Guidance for Dental Settings Dental health care personnel can find COVID-19-related information on the CDC’s Division of Oral Health website, which offers guidance and resources for clinics and health care facilities and recommen...
Conclusion: In patients with early-stage nasal NKTCL, our LVD-IMRT regimen produced excellent, durable therapeutic benefit in most patients, with acceptable toxicity and no acute mortality.
The monoclonal antibody m102.4, being developed to prevent and treat Hendra and Nipah virus infection, was well tolerated and safe in a first-in-human study.Reuters Health Information
Nipah virus is an emerging pathogenic paramyxovirus responsible for sporadic and isolated outbreaks of severe respiratory and neurologic disease in Southern Asia. As a zoonotic virus, disease can manifest in both animals and human with indigenous fruit bats acting as natural reservoirs of the virus. The effects of viral infection vary from acute respiratory distress to fatal encephalitis. There are currently no approved therapeutics or vaccines against the virus, and growing concerns that this highly pathogenic infection has the potential to cause larger epidemics capable of inflicting significant mortality burden.Like the...